LETERO 2.5MG

Letero 2.5mg is an anti-cancer medication classified as an aromatase inhibitor. It is recommended as a supportive treatment following the primary therapy or as a first-line option for postmenopausal women diagnosed with early and advanced hormone receptor-positive breast cancer. Given that elevated estrogen levels are known to contribute to breast cancer, this drug works by lowering the levels of this female reproductive hormone through the inhibition of the enzyme aromatase, which plays a crucial role in estrogen production. The primary goal of this medication is to hinder or prevent the growth and/or metastasis of cancer to other areas of the body.

It is important to inform your healthcare provider if you have not yet reached menopause, as this medication is ineffective for premenopausal women. Due to its tendency to lower female reproductive hormone levels, it is not recommended for menstruating women, as it may lead to fertility complications. Additionally, it is advisable to monitor your cholesterol levels, as this medication can increase them. There is also a possibility that it may reduce bone mineral density, so it is essential to discuss this with your doctor and consider regular monitoring of your bone health. Effective birth control is recommended during treatment and for at least three weeks after the final dose, as Letero 2.5mg can have implications for pregnancy when administered.